Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.